BioPharma-Reporter

Breaking news and analysis of the clinical development and manufacture of large molecule drugs. Old handle: @BioPharmaReport

[BioPharma-Reporter @BioPharmReport]

Pfizer has received a slap on the wrist from the @PMCPAUK but how much damage has this done and will it trigger internal changes at the pharma giant? Read our analysis
https://t.co/onyVx9ekHp

[BioPharma-Reporter @BioPharmReport]

Whether they recognise it or not, the entire pharma industry is involved in the business of health equity and championing it is critically important, @RKPimprint CCO of @Novartis told @RE_Pharma in her brilliant talk.
https://t.co/yzh3RglBRs

[BioPharma-Reporter @BioPharmReport]

Maya Martinez-Davis, president, US commercial at @GSK , outlined her approach to senior leadership @RE_Pharma

https://t.co/iHiquavBVq

[BioPharma-Reporter @BioPharmReport]

Professor Luigi, of the San Raffaele Telethon Institute for Gene Therapy in Milan, tells us about his fascinating career in gene therapy...
https://t.co/YI3qpm8S7W

[BioPharma-Reporter @BioPharmReport]

Big news for the pharma industry. A net positive or negative?

https://t.co/SEwDUcjgSg

[BioPharma-Reporter @BioPharmReport]

Watch: Bio Pharma Reporter hosted a fascinating conversation at @Phacilitate's Advanced Therapies Week - with speakers from @organabio, @TrakCel_, @CatalentPharma.

https://t.co/KGUZCNxFOq

[BioPharma-Reporter @BioPharmReport]

Weight loss drugs dominated the conversation at @Jefferies London Healthcare Conference. Read our recap of a panel discussing how CDMO's are approaching the market and getting ahead of the curve...
https://t.co/2jhahbDNZN

[BioPharma-Reporter @BioPharmReport]

Our first podcast of 2023 with Dr Sarah Bateup, therapy lead at @clerkenwell_uk...
https://t.co/86WB4kIvUq

[BioPharma-Reporter @BioPharmReport]

🚨 BREAKING NEWS: @SharpPackaging has acquired @BerkshireSM to offer a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry. https://t.co/lXsa8gjbYp

[BioPharma-Reporter @BioPharmReport]

While global biopharma firm @TakedaPharma used to be 'entirely reliant' on its CRO partners, the company is now striving to take control of its technology. Penny Carlson outlined the strategy at @veevasystems' R&D and Quality summit... https://t.co/hsvN1Uuy5H
#takeda #veeva

[BioPharma-Reporter @BioPharmReport]

A pleasure to speak with Lucy Jung, CEO of
@CharcoLtd, about the company's innovative wearable device, her career background and fascination for problem-solving...
https://t.co/yu59OaedZp

[BioPharma-Reporter @BioPharmReport]

Fantastic to speak with @AnebuloPharma's Simon Allen at Bio Boston about the rise of acute cannabinoid intoxication and the company's promising new drug to treat it...
https://t.co/G8BXi18bh5

[BioPharma-Reporter @BioPharmReport]

From the #BIO2023 floor: we spoke to @Cytiva CEO Emmanuel Ligner about how the company's recent integration with @PallBiotech is a "winning recipe" and how Cytiva is staying plugged into the industry... https://t.co/WQGiYoqIcY

[BioPharma-Reporter @BioPharmReport]

@avacta has acquired @corisbio, a European manufacturer of rapid diagnostic test kits...

https://t.co/UBQ4FRbXUN

[BioPharma-Reporter @BioPharmReport]

Earnings miss, lowered outlook for @CatalentPharma
https://t.co/8IcBq4fF9O

[BioPharma-Reporter @BioPharmReport]

.@AstraZeneca and @SanofiScience secure EU approval for antibody to prevent RSV in infants https://t.co/Y4kFSLXCZo

[BioPharma-Reporter @BioPharmReport]

It's today! Join us for our free webinar on bioprocessing 4.0. Find out about what today's smart factory looks like; the role bioprocessing 4.0 has to play in the current energy crisis - and much more. Register here to listen live or on-demand.
https://t.co/3Sq0nnTVnj

[BioPharma-Reporter @BioPharmReport]

Join us tomorrow for our free-to-attend webinar, Bioprocessing 4.0! Register here: https://t.co/3Sq0nnTVnj

[BioPharma-Reporter @BioPharmReport]

Join us next week for our free-to-attend webinar on Bioprocessing 4.0! Register here: https://t.co/71IEHprF19

[BioPharma-Reporter @BioPharmReport]

Synthego breaks ground on sgRNA manufacturing facility. The company plans to use the additional capacity to manufacture synthetic sgRNAs, used in the development of CRISPR-mediated cell and #gene therapies. @Synthego
#GeneTherapy #celltherapy #CRISPR
https://t.co/xPFp9s0Eq1